Melanoma Trials

From DolceraWiki
Jump to: navigation, search

To go back to the main page, click here

S.No. Drug Name Biological Name Developer Current Development Phase Additional Information Start Date Completion Date Source
11 - IMF-001 ImmunoFrontier, Inc. I The purpose of this study is assess the safety of administering repeated doses of IMF-001, a vaccine, to patients with solid tumors that express NY-ESO-1 antigen. If the vaccine is therapeutically useful, a second goal is to establish the maximum therapeutic dose to treat patients with NY-ESO-1 positive cancers. 2010 2011 Source
12 - Lipovaxin-MM Lipotek Pty Ltd I The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the bodys ability to destroy cancer cells in patients with metastatic melanoma. 2009 2011 Source
13 - PSMA/PRAME MannKind Corporation I Completed
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.
2007 2009 Source
14 - MKC1106-MT, MKCC1106-MT Mannkind Corporation I A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas. 2008 2010 Source
15 - MKC1106-MT Mannkind Corporation II The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma 2010 2012 Source
16 - V934/V935 Merck I Completed.
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
2008 2011 Source
17 - Pegylated Interferon-Alpha 2b NewLink Genetics II The purpose of this study is to determine the safety of giving subjects with advanced, recurrent or refractory melanoma the HyperAcute® Melanoma vaccine with a variant of a drug, called Interferon (PEG-Intron®) that is specially formulated to be given on a weekly basis (instead of daily). 2008 2011 Source
18 - - Sanofi-Aventis II Terminated
Objective was: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.
2008 2010 Source
19 - AdhTAP TapImmune Preclinical - - - -
20 - Dacarbazine (DTIC), Temozolomide (TMZ) Vical/AnGes III Approval possibly by 2013 2006 2012 Source




To go back to the main page, click here